eToro Group Ltd. continues to be a strong buy as it accelerates U.S. expansion through its $231 million acquisition of TradeZero and surpasses Q2 2026 earnings expectations. The company’s multi-asset platform shows strength with a 25% rise in net trading contribution and an 18% increase in funded accounts, reaching 4.28 million. Valuation remains attractive, trading at a discount compared to sector peers, supported by share buybacks and solid cash flow. Risks include cryptocurrency market cycles, regulatory challenges, and integration of TradeZero, but growth is expected to pick up again in 2027 with new products and AI enhancements.
For readers following eToro Group Ltd., here is Pluang's market snapshot as of Nov 02, 2026 21:03 WIB: Among 142 priced Financials-sector US stocks, 88 rose and 25 fell today. Notable movers include SEZL at USD 137.37 with a 1.88% increase, PURR at USD 10.81 down 1.82%, and BMNR at USD 20.54 up 1.78%. Typical hold times on Pluang range from 4 to 17 days for these stocks.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
